Display options
Cite
Bloch A, Ben-Chetrit E, Muszkat M, et al. Major bleeding caused by warfarin in a genetically susceptible patient. Pharmacotherapy. 2002;22(1):97-101doi: 10.1592/phco.22.1.97.33491.
Bloch, A., Ben-Chetrit, E., Muszkat, M., & Caraco, Y. (2002). Major bleeding caused by warfarin in a genetically susceptible patient. Pharmacotherapy, 22(1), 97-101. https://doi.org/10.1592/phco.22.1.97.33491
Bloch, Aharon, et al. "Major bleeding caused by warfarin in a genetically susceptible patient." Pharmacotherapy vol. 22,1 (2002): 97-101. doi: https://doi.org/10.1592/phco.22.1.97.33491
Bloch A, Ben-Chetrit E, Muszkat M, Caraco Y. Major bleeding caused by warfarin in a genetically susceptible patient. Pharmacotherapy. 2002 Jan;22(1):97-101. doi: 10.1592/phco.22.1.97.33491. PMID: 11794436.
Copy Download .nbib Format: NLM
Share it on

Pharmacotherapy. 2002 Jan;22(1):97-101. doi: 10.1592/phco.22.1.97.33491.

Major bleeding caused by warfarin in a genetically susceptible patient.

Pharmacotherapy

Aharon Bloch, Eldad Ben-Chetrit, Mordechai Muszkat, Yoseph Caraco

Affiliations

  1. Division of Medicine, Hadassah University Hospital, Jerusalem, Israel.

PMID: 11794436 DOI: 10.1592/phco.22.1.97.33491

Abstract

A 90-year-old woman was hospitalized for gastrointestinal bleeding. Although she had been receiving only warfarin 5 mg/day, her international normalized ratio (INR) was 66. Warfarin was discontinued, and her INR fell to 3.7 after transfusion of fresh-frozen plasma. However, it rose again spontaneously to 7.5. Eleven days after the last dose of warfarin had been administered, it was still detectable in the patient's plasma, indicating that impaired warfarin clearance may have caused an enhanced anticoagulation effect. Genetic analysis of the cytochrome P450 (CYP) isoenzyme 2C9, which mediates the major deactivating pathway of S-warfarin, revealed that the patient was a compound heterozygote carrying two variant alleles: CYP2C9*2 and CYP2C9*3. The patient's enhanced sensitivity to warfarin 5 mg/day can be ascribed to decreased clearance of S-warfarin secondary to genetic alteration of the gene encoding CYP2C9, resulting in a life-threatening complication.

Substances

MeSH terms

Publication Types